ArticleCancer diagnosis & prognosis
Lipid Profiles in Breast Cancer: Clinical Associations and Biological Insights.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alterations in lipid metabolism are increasingly recognized as important contributors to breast cancer biology. Lipids regulate membrane structure, intracellular signaling, and energy homeostasis, and cancer cells undergo lipid metabolic reprogramming to support tumor growth and progression. This narrative review summarizes current evidence on the relationship between circulating lipid profiles and breast cancer risk, tumor characteristics, and outcomes, with a focus on total cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), as well as the effects of endocrine therapies on lipid metabolism. Epidemiological studies show heterogeneous and lipid-specific associations that vary by menopausal status, tumor subtype, and study design. Triglycerides and LDL-C are most consistently linked to aggressive tumor features and disease progression, whereas total cholesterol appears to reflect broader metabolic and hormonal disturbances rather than a direct causal role. HDL-C shows inconsistent associations, likely due to functional heterogeneity not captured by circulating HDL-C levels alone. Mechanistic studies support a role for lipid metabolism in promoting tumor growth, invasion, angiogenesis, and therapy resistance. Endocrine therapies further modify lipid profiles, with tamoxifen generally reducing total cholesterol and LDL-C while increasing triglycerides, and aromatase inhibitors showing largely neutral effects in recent population-based studies. Overall, circulating lipid fractions are not suitable as standalone biomarkers but may provide clinically relevant information when interpreted in the context of tumor biology, metabolic health, and long-term survivorship care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.